Skip to main content
Explore URMC

menu

Leukemia: Phase I Testing the Addition of Inotuzumab Ozogamicin, to Usual Chemotherapy in Relapsed and Refractory Acute Leukemia

Research Question:
The purpose of this study is to test the safety of the experimental drug inotuzumab ozogamicin at different doses to find out what effects, if any, it has on people.

Basic Study Information

Purpose:
The purpose of this study is to test the safety of the experimental drug inotuzumab ozogamicin at different doses to find out what effects, if any, it has on people. The researchers also want to determine the effects, good and/or bad, of adding inotuzumab ozogamicin to regular chemotherapy with cyclophosphamide, vincristine and prednisone (CVP). While researchers hope that adding inotuzumab ozogamicin will be a better treatment, there is no proof of this.

Location: Cancer Center
Study Web URL:  http://clinicaltrials.gov/ct2/show/NCT01925131?term=S1312&rank=1
Study Reference #: CLEU-13096

Lead Researcher (Principal Investigator)

Lead Researcher: Michael Becker, MD

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 276-4415
Email: Haley_Misch@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Acute lymphoblastic leukemia [ALL]

More information about Leukemia

More information about Leukemia, B-Cell

More information about Lymphoid leukemia, acute

Return to Search